Auris Medical's tinnitus failure sends stock plummeting

19 August 2016

Nearly 60% was wiped off the share price of Swiss biopharma Auris Medical Holding (Nasdaq: EARS) on Thursday after it announced the failure of a Phase III trial of Keyzilen (AM-101) in acute inner ear tinnitus.

The otolaryngology specialist's product did not meet the co-primary efficacy endpoints in the TACTT2 trial of statistically-significant changes in tinnitus loudness and tinnitus burden, compared to placebo.

Auris Medical’s chief executive Thomas Meyer said the company was disappointed at this outcome, which led its share price to fall from $5.35 at the end of Wednesday’s trading, to $2.15 by Thursday’s close.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK